VBL Therapeutics Initiates Phase 2 Clinical Trial Of VB-201 In Patients With Psoriasis

VBL Therapeutics announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis...